December 5-8, 2020; Online at https://www.hematology.org/meetings/annual-meeting
Among the first 10 study participants with ≥ 3 months of follow-up, CTX001 infusion achieved cessation of pRBC transfusions for TDT patients, and eliminated veno-occlusive events for severe SCD patients.